Fig. 4From: Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in ChinaIncremental Cost-Effectiveness Rate scatter. Incremental cost-effectiveness scatterplot of the result of the probabilistic sensitivity analysis. Each point represents a simulation. Ellipse represents 95% confidence interval ellipseBack to article page